AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16825681 — intervention group
Group type: EXPERIMENTAL
Intervention: Partially hydrogenated soybean oil
Number of subjects: 15
Study 16825681 — intervention group
Group type: COMPARATOR
Intervention: Soybean oil
Number of subjects: 15
Study 16825681 — intervention group
Group type: COMPARATOR
Intervention: Canola oil
Number of subjects: 15
Study 12513955 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentinel lymph node biopsy for head and neck melanoma
Number of subjects: 2610
Study 12513955 — intervention group
Group type: COMPARATOR
Intervention: Sentinel lymph node biopsy for truncal melanoma
Number of subjects: 2610
Study 12513955 — intervention group
Group type: COMPARATOR
Intervention: Sentinel lymph node biopsy for extremity melanoma
Number of subjects: 2610
Study 16957540 — intervention group
Group type: EXPERIMENTAL
Intervention: Vagus Nerve Stimulation (VNS) + Electroconvulsive Therapy (ECT)
Number of subjects: 205
Study 16957540 — intervention group
Group type: COMPARATOR
Intervention: Vagus Nerve Stimulation (VNS)
Number of subjects: 205
Study 10227615 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate 6 mg/kg/day
Number of subjects: 86
Study 10227615 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 8907570 — intervention group
Group type: EXPERIMENTAL
Intervention: Insertion of new shunts
Number of subjects: 34
Study 8907570 — intervention group
Group type: COMPARATOR
Intervention: Dilatation
Number of subjects: 34
Study 8907570 — intervention group
Group type: COMPARATOR
Intervention: Explanted livers assessment
Number of subjects: 34
Study 1684909 — intervention group
Group type: EXPERIMENTAL
Intervention: D-verapamil (DVPM) 800 mg/day
Number of subjects: 10
Study 1684909 — intervention group
Group type: EXPERIMENTAL
Intervention: D-verapamil (DVPM) 1200 mg/day
Number of subjects: 10
Study 1684909 — intervention group
Group type: EXPERIMENTAL
Intervention: D-verapamil (DVPM) 600 mg/day
Number of subjects: 10
Study 1684909 — intervention group
Group type: EXPERIMENTAL
Intervention: D-verapamil (DVPM) 150-300 mg 6 h
Number of subjects: 10
Study 7043162 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 or 10 g GABA (intervention)
Number of subjects: 12
Study 7043162 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg muscimol (intervention)
Number of subjects: 12
Study 30606137 — intervention group
Group type: COMPARATOR
Intervention: Supervised group exercise (GROUP)
Number of subjects: 59
Study 30606137 — intervention group
Group type: COMPARATOR
Intervention: Home-based exercise (HOME)
Number of subjects: 59
Study 30606137 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal training (PT)
Number of subjects: 59
Study 28653400 — intervention group
Group type: EXPERIMENTAL
Intervention: Panobinostat plus bortezomib and dexamethasone
Number of subjects: 0
Study 28653400 — intervention group
Group type: EXPERIMENTAL
Intervention: Panobinostat
Number of subjects: 0
Study 28653400 — intervention group
Group type: COMPARATOR
Intervention: Bortezomib and dexamethasone
Number of subjects: 0
Study 28653400 — intervention group
Group type: EXPERIMENTAL
Intervention: Panobinostat and bortezomib
Number of subjects: 0
Study 26467819 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (60-70% VO2peak for 45 min, 3 days per week) for 8 weeks
Number of subjects: 32
Study 25091663 — intervention group
Group type: EXPERIMENTAL
Intervention: 116E rotavirus vaccine
Number of subjects: 6799
Study 25091663 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6799
Study 22751691 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise (AE)
Number of subjects: 45
Study 22751691 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Exercise (RE)
Number of subjects: 45
Study 22751691 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 45
Study 19669018 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified fluid gelatin and normal saline (NS)
Number of subjects: 40
Study 19669018 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (NS)
Number of subjects: 40
Study 17317370 — intervention group
Group type: COMPARATOR
Intervention: Rosuvastatin 40 mg alone
Number of subjects: 469
Study 17317370 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 40 mg + Ezetimibe 10 mg
Number of subjects: 469
Study 15076156 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoprenaline (Iso) 8 microg/kg per min
Number of subjects: 41
Study 15076156 — intervention group
Group type: COMPARATOR
Intervention: Placebo (glucose 5%)
Number of subjects: 41
Study 11274548 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple-dose gadodiamide (0.3 mmol/kg)
Number of subjects: 105
Study 11274548 — intervention group
Group type: COMPARATOR
Intervention: Single-dose gadodiamide (0.1 mmol/kg)
Number of subjects: 105
Study 9737831 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelaic acid 20% cream and glycolic acid lotion
Number of subjects: 0
Study 9737831 — intervention group
Group type: COMPARATOR
Intervention: Tretinoin 0.025% cream
Number of subjects: 0
Study 7913292 — intervention group
Group type: EXPERIMENTAL
Intervention: eformoterol 24 micrograms twice daily
Number of subjects: 7
Study 7913292 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 7
Study 30585747 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet lemonade
Number of subjects: 12
Study 30585747 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular lemonade
Number of subjects: 12
Study 30585747 — intervention group
Group type: COMPARATOR
Intervention: Baseline (controlled diet only)
Number of subjects: 12
Study 28323322 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent hypoxia-hyperoxia training (IHHT)
Number of subjects: 46
Study 28323322 — intervention group
Group type: COMPARATOR
Intervention: Sham-IHHT (breathing room air, O2 at 21%)
Number of subjects: 46
Study 25617774 — intervention group
Group type: EXPERIMENTAL
Intervention: Male‐Trauma Recovery Empowerment Model (M‐TREM)
Number of subjects: 230
Study 25617774 — intervention group
Group type: EXPERIMENTAL
Intervention: Seeking Safety (SS)
Number of subjects: 230
Study 25617774 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 230
Study 25617774 — intervention group
Group type: EXPERIMENTAL
Intervention: Seeking Safety (SS) and Male‐Trauma Recovery Empowerment Model (M‐TREM)
Number of subjects: 230
Study 24317380 — intervention group
Group type: EXPERIMENTAL
Intervention: HOMEfit exercise intervention
Number of subjects: 209
Study 24317380 — intervention group
Group type: EXPERIMENTAL
Intervention: N4 patients (1,214) invited to final assessment
Number of subjects: 209
Study 24317380 — intervention group
Group type: EXPERIMENTAL
Intervention: N5 patients (434) attended practice screening
Number of subjects: 209
Study 24317380 — intervention group
Group type: EXPERIMENTAL
Intervention: N6 patients (209) randomized
Number of subjects: 209
Study 21144515 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous nitroglycerin (200 μg)
Number of subjects: 40
Study 21144515 — intervention group
Group type: COMPARATOR
Intervention: Normal saline solution (control)
Number of subjects: 40
Study 18295465 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula F11 (CH:AL, 20:80 IPC:Imwitor 900 K, 3:1)
Number of subjects: 0
Study 18295465 — intervention group
Group type: COMPARATOR
Intervention: Immediate release Ikorel tablet
Number of subjects: 0
Study 16863527 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc sulfate 100 mg three times per day
Number of subjects: 25
Study 16863527 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 12645862 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg lignocaine
Number of subjects: 153
Study 12645862 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg lignocaine
Number of subjects: 153
Study 12645862 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg lignocaine
Number of subjects: 153
Study 11289670 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (200,000 IU, 2 doses at baseline, additional doses at 4 and 8 months)
Number of subjects: 687
Study 11289670 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 687
Study 11289670 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding for longer than 18 months
Number of subjects: 687
Study 11289670 — intervention group
Group type: EXPERIMENTAL
Intervention: Children over two years of age
Number of subjects: 687
Study 11289670 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with repeated diagnoses of malaria
Number of subjects: 687
Study 9316621 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIL-1 beta (200 ng/kg)
Number of subjects: 54
Study 9316621 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIL-1 beta (postchemotherapy)
Number of subjects: 54
Study 9316621 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIL-1 beta (all dose levels)
Number of subjects: 54
Study 8451780 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ) 300 mg
Number of subjects: 6
Study 8451780 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine 50 mg
Number of subjects: 6
Study 3092053 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (tapered doses)
Number of subjects: 40
Study 3092053 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 3092053 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Placebo and Diazepam)
Number of subjects: 40
Study 31699671 — intervention group
Group type: EXPERIMENTAL
Intervention: High CXCL9 expression
Number of subjects: 557
Study 31699671 — intervention group
Group type: EXPERIMENTAL
Intervention: High CXCL9 expression in triple negative disease
Number of subjects: 557
Study 31699671 — intervention group
Group type: EXPERIMENTAL
Intervention: High CXCL13 expression in luminal-HER2 disease
Number of subjects: 557
Study 31699671 — intervention group
Group type: EXPERIMENTAL
Intervention: Low CXCL13 and high CXCL9 expression
Number of subjects: 557
Study 30830119 — intervention group
Group type: EXPERIMENTAL
Intervention: Choline alfoscerate (ChA) 14 mg/kg
Number of subjects: 80
Study 30830119 — intervention group
Group type: EXPERIMENTAL
Intervention: Succinate combination (SC) 0.5 mg/kg
Number of subjects: 80
Study 30830119 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ChA and SC
Number of subjects: 80
Study 30830119 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control group)
Number of subjects: 80
Study 27062963 — intervention group
Group type: EXPERIMENTAL
Intervention: Decaffeinated green tea extract (GTE) 1500 mg daily for 4 weeks
Number of subjects: 80
Study 27062963 — intervention group
Group type: COMPARATOR
Intervention: Placebo (cellulose)
Number of subjects: 80
Study 24206233 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard audiovisual interventions (experimental group)
Number of subjects: 0
Study 24206233 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo audiovisual interventions (placebo group)
Number of subjects: 0
Study 24206233 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study 23200974 — intervention group
Group type: COMPARATOR
Intervention: Topical 2% lignocaine jelly
Number of subjects: 40
Study 23200974 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% lignocaine ICSB
Number of subjects: 40
Study 20739853 — intervention group
Group type: EXPERIMENTAL
Intervention: Good glucose control (target glucose level of 130 mg/dL)
Number of subjects: 208
Study 20739853 — intervention group
Group type: COMPARATOR
Intervention: Poor glucose control (glucose levels above 130 mg/dL)
Number of subjects: 208
Study 28438257 — intervention group
Group type: EXPERIMENTAL
Intervention: Test allopurinol tablet (300 mg)
Number of subjects: 18
Study 28438257 — intervention group
Group type: COMPARATOR
Intervention: Reference allopurinol tablet (300 mg)
Number of subjects: 18
Study 16168728 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk DAT1 ADHD group
Number of subjects: 42
Study 16168728 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-risk DAT1 ADHD group
Number of subjects: 42
Study 16168728 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 42
Study 12586856 — intervention group
Group type: EXPERIMENTAL
Intervention: Power training (PT)
Number of subjects: 39
Study 12586856 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training (ST)
Number of subjects: 39
Study 12586856 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 39
Study 10673880 — intervention group
Group type: EXPERIMENTAL
Intervention: Intubating Laryngeal Mask Airway (ILMA)
Number of subjects: 60
Study 10673880 — intervention group
Group type: COMPARATOR
Intervention: Direct Laryngoscopy
Number of subjects: 60
Study 10673880 — intervention group
Group type: COMPARATOR
Intervention: Face Mask
Number of subjects: 60
Study 8840352 — intervention group
Group type: EXPERIMENTAL
Intervention: Arecoline 1 mg/day
Number of subjects: 9
Study 8840352 — intervention group
Group type: EXPERIMENTAL
Intervention: Arecoline 4 mg/day
Number of subjects: 9
Study 8840352 — intervention group
Group type: EXPERIMENTAL
Intervention: Arecoline 16 mg/day
Number of subjects: 9
Study 8840352 — intervention group
Group type: EXPERIMENTAL
Intervention: Arecoline 28 mg/day
Number of subjects: 9
Study 8840352 — intervention group
Group type: EXPERIMENTAL
Intervention: Arecoline 40 mg/day
Number of subjects: 9
Study 1751666 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrous carbon enterosorbent VESTA in tablets for 14 days (group I)
Number of subjects: 46
Study 1751666 — intervention group
Group type: COMPARATOR
Intervention: Parenteral administration of hemostimulants, hemosubstitutes and detoxicants (group II)
Number of subjects: 46
Study 6818596 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpromazine (CPZ) 12.5 mg
Number of subjects: 25
Study 6818596 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpromazine (CPZ) 25.0 mg
Number of subjects: 25
Study 6818596 — intervention group
Group type: COMPARATOR
Intervention: Control (no chlorpromazine)
Number of subjects: 25
Study 30205242 — intervention group
Group type: EXPERIMENTAL
Intervention: OCT-guided stent implantation
Number of subjects: 1200
Study 30205242 — intervention group
Group type: COMPARATOR
Intervention: Standard angiographic-guided implantation
Number of subjects: 1200
Study 26803719 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental arm (NRTIs withdrawn)
Number of subjects: 90
Study 26803719 — intervention group
Group type: COMPARATOR
Intervention: Control arm (NRTIs maintained)
Number of subjects: 90
Study 26803719 — intervention group
Group type: EXPERIMENTAL
Intervention: Both arms
Number of subjects: 90
Study 23685919 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom contoured shapes
Number of subjects: 30
Study 23685919 — intervention group
Group type: COMPARATOR
Intervention: Commercially shaped cushion
Number of subjects: 30
Study 22811499 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-centered adherence intervention
Number of subjects: 280
Study 22811499 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 280
Study 20643092 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV-16/18 AS04-adjuvanted vaccine
Number of subjects: 433
Study 18543380 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 min Qigong exercise
Number of subjects: 41
Study 18543380 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 min Qigong exercise
Number of subjects: 41
Study 15813835 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsules taken just before meals (schedule A)
Number of subjects: 24
Study 15813835 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsules taken just after meals (schedule B)
Number of subjects: 24
Study 15813835 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsules taken along with meals (schedule C)
Number of subjects: 24
Study 12748463 — intervention group
Group type: EXPERIMENTAL
Intervention: EE/levonorgestrel (0.3 mg ethinyl estradiol / 0.15 mg levonorgestrel)
Number of subjects: 34
Study 12748463 — intervention group
Group type: EXPERIMENTAL
Intervention: EE/desogestrel (0.3 mg ethinyl estradiol / 0.15 mg desogestrel)
Number of subjects: 34
Study 12748463 — intervention group
Group type: EXPERIMENTAL
Intervention: EE/desogestrel
Number of subjects: 34
Study 12748463 — intervention group
Group type: EXPERIMENTAL
Intervention: EE/levonorgestrel
Number of subjects: 34
Study 11097672 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.125% bupivacaine
Number of subjects: 10
Study 11097672 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine
Number of subjects: 10
Study 11097672 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine
Number of subjects: 10
Study 11097672 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75% bupivacaine
Number of subjects: 10
Study 11097672 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.125% levobupivacaine
Number of subjects: 10
Study 11097672 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% levobupivacaine
Number of subjects: 10
Study 11097672 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% levobupivacaine
Number of subjects: 10
Study 11097672 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75% levobupivacaine
Number of subjects: 10
Study 11097672 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 10
Study 8792107 — intervention group
Group type: EXPERIMENTAL
Intervention: Micral-Test strip
Number of subjects: 530
Study 8792107 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooled Micral-Test result (> or = 15 mg/l)
Number of subjects: 530
Study 1352370 — intervention group
Group type: COMPARATOR
Intervention: RU 42 173 (0.25 mg single oral dose)
Number of subjects: 12
Study 6397914 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal combination Dietosan (species)
Number of subjects: 40
Study 6397914 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal combination Dietosan (disperg)
Number of subjects: 40
Study 6397914 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal combination Dietosan (species) with glybenclamide
Number of subjects: 40
Study 6397914 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal combination Dietosan (disperg) with glybenclamide
Number of subjects: 40
Study 6397914 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal combination Dietosan (species and disperg)
Number of subjects: 40
Study 30964820 — intervention group
Group type: EXPERIMENTAL
Intervention: Oropharyngeal colostrum administration (0.2 mL every 2 hours for 48 hours)
Number of subjects: 113
Study 30964820 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sterile water, 0.2 mL every 2 hours for 48 hours)
Number of subjects: 113
Study 30964820 — intervention group
Group type: EXPERIMENTAL
Intervention: Oropharyngeal colostrum administration
Number of subjects: 113
Study 30964820 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sterile water)
Number of subjects: 113
Study 28372580 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical decision-making support system (CDMSS) using USSD-based text messaging of standard emergency obstetric and neonatal protocols.
Number of subjects: 16
Study 28372580 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 16
Study 27223302 — intervention group
Group type: EXPERIMENTAL
Intervention: Dark chocolate (65 g)
Number of subjects: 92
Study 27223302 — intervention group
Group type: EXPERIMENTAL
Intervention: Yerba mate (3 g)
Number of subjects: 92
Study 27223302 — intervention group
Group type: COMPARATOR
Intervention: Chocolate-placebo
Number of subjects: 92
Study 27223302 — intervention group
Group type: COMPARATOR
Intervention: Mate-placebo
Number of subjects: 92
Study 23875574 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual working memory load
Number of subjects: 0
Study 23875574 — intervention group
Group type: EXPERIMENTAL
Intervention: Spatial working memory load
Number of subjects: 0
Study 23875574 — intervention group
Group type: EXPERIMENTAL
Intervention: Phonological working memory load
Number of subjects: 0
Study 23875574 — intervention group
Group type: COMPARATOR
Intervention: Single-task (no working memory load)
Number of subjects: 0
Study 22424011 — intervention group
Group type: EXPERIMENTAL
Intervention: Worsening renal function III (WRF III)
Number of subjects: 566
Study 22424011 — intervention group
Group type: EXPERIMENTAL
Intervention: Worsening renal function I (WRF I)
Number of subjects: 566
Study 22424011 — intervention group
Group type: EXPERIMENTAL
Intervention: Worsening renal function II (WRF II)
Number of subjects: 566
Study 22424011 — intervention group
Group type: EXPERIMENTAL
Intervention: High doses of loop diuretics and spironolactone use
Number of subjects: 566
Study 22424011 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin‐converting enzyme inhibitor, angiotensin receptor blocker, and β‐blocker use
Number of subjects: 566
Study 22424011 — intervention group
Group type: EXPERIMENTAL
Intervention: Allocation to N‐terminal pro‐B‐type natriuretic peptide‐guided management
Number of subjects: 566
Study 22424011 — intervention group
Group type: EXPERIMENTAL
Intervention: Death, death or hospitalization, and death or HF hospitalization
Number of subjects: 566
Study 19389746 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized visual perception rehabilitation programme with interactive patient-computer interface applying motion tracking technology
Number of subjects: 16
Study 19389746 — intervention group
Group type: COMPARATOR
Intervention: PSS CogRehab program
Number of subjects: 16
Study 17142065 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised Exercise Programme (SEP) for 3 months, 60 minutes, three times a week
Number of subjects: 70
Study 17142065 — intervention group
Group type: COMPARATOR
Intervention: Conservative Medical Therapy (CMT)
Number of subjects: 70
Study 16009955 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole 1 mg/d
Number of subjects: 448
Study 16009955 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen 20 mg/d
Number of subjects: 448
Study 10989854 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 microg/kg remifentanil and 3.5 mg/kg propofol
Number of subjects: 80
Study 10989854 — intervention group
Group type: COMPARATOR
Intervention: 0.4 mg/kg rocuronium
Number of subjects: 80
Study 9192229 — intervention group
Group type: EXPERIMENTAL
Intervention: Education through monthly newsletters and semiannual classes on nutrition and exercise
Number of subjects: 1226
Study 9192229 — intervention group
Group type: EXPERIMENTAL
Intervention: Education plus a lottery incentive for participation
Number of subjects: 1226
Study 9192229 — intervention group
Group type: COMPARATOR
Intervention: No-contact control
Number of subjects: 1226